business news
Insiders Buy Shares at Achillion Pharmaceuticals, ChemoCentryx, and Walter Energy
By
Jonathan Moreland
Nov 04, 2013 10:57 am
Plus, a purchase at Accelrys.
PRINT
Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside purchases recently filed with the SEC.
Notable Purchases:
For more insider trades, see the charts below.
In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."
Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.
At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.
Jonathan Moreland is also the author of "Profit From Legal Insider Trading."
Notable Purchases:
- Boston-based investment adviser Ra Capital Management bought 1,186,007 shares of biopharmaceutical company Achillion Pharmaceuticals (NASDAQ:ACHN) for $2,902,711. Achillion focuses on the discovery, development, and commercialization of treatments for infectious diseases. This purchase was filed with the SEC on the same day -- Monday, September 30 -- as a major sale of company stock by QVT Associates GP LLC.
- The private equity firm BVF Partners LP bought 336,225 shares of biopharmaceutical company ChemoCentryx (NASDAQ:CCXI) for $1,676,808. ChemoCentryx develops oral-administered therapeutics for the treatment of autoimmune diseases, inflammatory diseases, and cancer.
- The investment firm RGM Capital bought 119,460 shares of scientific informatics company Accelrys (NASDAQ:ACCL) for $1,111,992.
- David Beatty, a director at metallurgical coals producer and exporter Walter Energy (NYSE:WLT), bought 10,000 shares of company stock for $168,700.
For more insider trades, see the charts below.
| #: | Filer Name | Insider Titles | Company Name | Ticker |
Trans Type |
Dollar Value |
|---|---|---|---|---|---|---|
|
1
|
DIR
|
AB
|
$3,625,176
|
|||
|
2
|
BO
|
B
|
$2,902,711
|
|||
|
3
|
BO
|
B
|
$1,676,808
|
|||
|
4
|
BO
|
B
|
$1,111,992
|
|||
|
5
|
BO
|
JB*
|
$1,100,000
|
|||
|
6
|
DIR
|
JB*
|
$650,000
|
|||
|
7
|
DIR,BO
|
B
|
$568,710
|
|||
|
8
|
CEO,CB,BO
|
B
|
$345,598
|
|||
|
9
|
CEO,DIR
|
JB*
|
$280,000
|
|||
|
10
|
DIR
|
B
|
$168,700
|
| #: | Filer Name | Insider Titles | Company Name | Ticker |
Trans Type |
Dollar Value |
|---|---|---|---|---|---|---|
|
1
|
DIR
|
AS
|
$142,506,400
|
|||
|
2
|
BO
|
JS*
|
$109,326,912
|
|||
|
3
|
DIR,BO
|
JS*
|
$49,000,000
|
|||
|
4
|
PR
|
S
|
$6,924,840
|
|||
|
5
|
DIR
|
S
|
$2,938,957
|
|||
|
6
|
CEO,DIR
|
AS
|
$2,722,920
|
|||
|
7
|
DIR
|
S
|
$2,460,587
|
|||
|
8
|
VP,COO
|
S
|
$2,146,000
|
|||
|
9
|
DIR
|
S
|
$1,993,553
|
|||
|
10
|
VP,CFO
|
S
|
$1,567,923
|
Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes
An important note from Jonathan Moreland, founder of Insider Insights:In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."
Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.
At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.
Jonathan Moreland is also the author of "Profit From Legal Insider Trading."
No positions in stocks mentioned.
